View in EDS

Update About the Management of Low-Density Lipoprotein Cholesterol and Hypertriglyceridemia in Lower Extremity Peripheral Artery Disease Patients: Consensus of the French Society of Vascular Medicine and the French Society for Vascular and Endovascular Surgery

Saved in:
Bibliographic Details
Title: Update About the Management of Low-Density Lipoprotein Cholesterol and Hypertriglyceridemia in Lower Extremity Peripheral Artery Disease Patients: Consensus of the French Society of Vascular Medicine and the French Society for Vascular and Endovascular Surgery
Authors: Guillaume Mahé, Gudrun Boge, Alessandra Bura-Rivière, Nabil Chakfé, Joël Constans, Yann Goueffic, Philippe Lacroix, Claire Le Hello, Gilles Pernod, Antonia Perez-Martin, Jean Picquet, Muriel Sprynger, Thomas Behar, Xavier Bérard, Christophe Bonnin, Christophe Breteau, Dominique Brisot, Franck Chleir, Clarisse Choquenet, Raphael Coscas, Grégoire Detriché, Marie Elias, Khalil Ezzaki, Patrick Feugier, Sandrine Fiori, Sébastien Gaertner, Catherine Gaillard, Céline Gaudout, Charles-Emmanuel Gauthier, Yannick Georg, Adrien Hertault, Elixène Jean-Baptiste, Adrien Kaladji, Joëlle Laffont, Damien Lanéelle, Jean-Pierre Laroche, Anne Lejay, Tiphanie Loric, Anne-Laure Madika, Betty Magnou, Jean-Patrick Maillard, Julie Malloizel-Delaunay, Gilles Miserey, Alain Moukarzel, Claire Mounier-Vehier, Bahaa Nasr, Marie-Line Nelzy, Philippe Nicolini, Jacques-Yves Phelipot, Jean Sabatier, Simon Soudet, Anne Tissot, Laurent Tribout, Jean-Claude Wautrecht, Charles Zarca, Anne Zuber
Source: Annals of Vascular Surgery. 100:148-154
Publisher Information: Elsevier BV, 2024.
Publication Year: 2024
Subject Terms: Hypertriglyceridemia, Consensus, Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects, Peripheral Arterial Disease/surgery, Cardiology, Cholesterol, LDL, Systèmes cardiovasculaire & respiratoire, Hypertriglyceridemia/complications, Sciences de la santé humaine, Hypertriglyceridemia/diagnosis, 3. Good health, Peripheral Arterial Disease, Treatment Outcome, Peripheral Arterial Disease/diagnosis, Hypertriglyceridemia/drug therapy, Cardiovascular & respiratory systems, Atrial Fibrillation, Humans, Surgery, Human health sciences, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine
Description: A French intersociety consensus on behalf the Société Française de Médecine Vasculaire and the Société de Chirurgie Vasculaire et Endovasculaire was proposed in 2021 for the management of patients with lower extremity peripheral artery disease (LEAD). Recent studies have been published and an update of this consensus about the management of low-density lipoprotein cholesterol (LDLc) and hypertriglyceridemia was required.A steering committee of 12 vascular physicians and surgeons defined questions of interest about LDLc and hypertriglyceridemia management. A French expert panel voted the proposals. Consensus was considered to have been achieved if more than 80% of the responses corresponded to either "Agreement" or "Disagreement".Among the 56 experts who were asked to participate, 46 (82%) accepted. After the first round of the Delphi procedure, the 4 proposals reached consensus. The following suggestions and recommendations were approved: 1. For LEAD patients treated by the highest tolerated statin dose ± ezetimibe and who have an LDLc ≥0.70 g/L, we recommend adding a proprotein convertase subtilisin/kexin type 9 inhibitor. 2. For LEAD patients treated by statin and who have elevated triglyceride level between ≥150 mg/dL and ≤500 mg/dL, we suggest adding Icosapent Ethyl. 3. Before adding Icosapent Ethyl in LEAD patients treated with statin, we suggest looking for symptoms that may suggest atrial fibrillation. 4. For LEAD patients treated by Icosapent Ethyl and who have symptoms that suggest atrial fibrillation, we recommend performing an electrocardiogram.This update will help clinicians to improve LEAD patient management.
Document Type: Article
Language: English
ISSN: 0890-5096
DOI: 10.1016/j.avsg.2023.08.023
Access URL: https://pubmed.ncbi.nlm.nih.gov/37806655
Rights: Elsevier TDM
Accession Number: edsair.doi.dedup.....50afb3a6e26f36478a577722370e812e
Database: OpenAIRE
Description
Abstract:A French intersociety consensus on behalf the Société Française de Médecine Vasculaire and the Société de Chirurgie Vasculaire et Endovasculaire was proposed in 2021 for the management of patients with lower extremity peripheral artery disease (LEAD). Recent studies have been published and an update of this consensus about the management of low-density lipoprotein cholesterol (LDLc) and hypertriglyceridemia was required.A steering committee of 12 vascular physicians and surgeons defined questions of interest about LDLc and hypertriglyceridemia management. A French expert panel voted the proposals. Consensus was considered to have been achieved if more than 80% of the responses corresponded to either "Agreement" or "Disagreement".Among the 56 experts who were asked to participate, 46 (82%) accepted. After the first round of the Delphi procedure, the 4 proposals reached consensus. The following suggestions and recommendations were approved: 1. For LEAD patients treated by the highest tolerated statin dose ± ezetimibe and who have an LDLc ≥0.70 g/L, we recommend adding a proprotein convertase subtilisin/kexin type 9 inhibitor. 2. For LEAD patients treated by statin and who have elevated triglyceride level between ≥150 mg/dL and ≤500 mg/dL, we suggest adding Icosapent Ethyl. 3. Before adding Icosapent Ethyl in LEAD patients treated with statin, we suggest looking for symptoms that may suggest atrial fibrillation. 4. For LEAD patients treated by Icosapent Ethyl and who have symptoms that suggest atrial fibrillation, we recommend performing an electrocardiogram.This update will help clinicians to improve LEAD patient management.
ISSN:08905096
DOI:10.1016/j.avsg.2023.08.023